+

WO2006010589A2 - Mousse en gel post-moussant - Google Patents

Mousse en gel post-moussant Download PDF

Info

Publication number
WO2006010589A2
WO2006010589A2 PCT/EP2005/008108 EP2005008108W WO2006010589A2 WO 2006010589 A2 WO2006010589 A2 WO 2006010589A2 EP 2005008108 W EP2005008108 W EP 2005008108W WO 2006010589 A2 WO2006010589 A2 WO 2006010589A2
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
formulations according
treatment
amount
pharmacologically active
Prior art date
Application number
PCT/EP2005/008108
Other languages
English (en)
Other versions
WO2006010589A3 (fr
Inventor
Barry Hunt
Original Assignee
Mipharm S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004904260A external-priority patent/AU2004904260A0/en
Application filed by Mipharm S.P.A. filed Critical Mipharm S.P.A.
Publication of WO2006010589A2 publication Critical patent/WO2006010589A2/fr
Publication of WO2006010589A3 publication Critical patent/WO2006010589A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • This invention relates to formulations adapted particularly for insertion of a pharmacologically active agent into a body cavity for systemic treatment or prophylaxis of a medical condition in the patient being treated, or for localised treatment or prophylaxis of the mucosal surface of the cavity of the patient into which the formulation is inserted. More particularly this invention relates to pharmaceutical compositions suited to the treatment or prophylaxis of systemic medical conditions, or of localised medical conditions of the mucosa. The invention is also concerned with methods of treatment of bacterial or fungal mucosal infections.
  • the mucosal surfaces of the human body represent a relatively unexplored mechanism by which pharmacologically active agents may be delivered to patients requiring either local or systemic prophylactic or medical treatment.
  • Post-foaming gel mousses have been used for some time in the toiletry industry, especially for shaving gels such as for example in US 5,186,857 (RAMIREZ et al), US 5,500,211 (GEORGE et al), and US 6,165,456 (BARNET et al).
  • the main foaming agents (propellants) used in these products are n-pentane and/or iso-pentane. These allow the product to be dispensed as a non-expanded gel, which then expands slowly to a foam, mainly from the warming effect of skin temperature. Neither of these materials is approved for use in pharmaceutical products.
  • the pharmaceutically-acceptable propellants all have too high a pressure to be used in a post- foaming gel, as they cause rapid expansion of the gel, causing the pain or discomfort referred to previously.
  • CFC propellants eg combinations of CFCs 11, 12 and 114, but these are now prohibited because of their effect on the ozone layer.
  • a formulation suited to the delivery of pharmacologically active agent into the body cavity of a patient to be treated said formulation comprising foaming agents, surfactants, thickeners and optionally when required, vapour pressure reducers.
  • the foaming agent is a pharmaceutically acceptable propellant and more preferably, the foaming agent is n-butane.
  • the formulation is a gel at room temperature, until upon application, it expands into a mousse or foam at a rate so as to not cause discomfort, and to a degree sufficient to adequately coat the mucosal surface of the body cavity.
  • the term “comprising” shall be taken to mean that the subject matter to which it relates may contain additional components, features, characteristics, ingredients or combinations thereof which are not specifically mentioned, and shall not be taken so as to exclude additional components, features, characteristics, ingredients or combinations thereof which are not specifically mentioned.
  • the term “pharmacologically active agent” shall be taken to mean any chemical substance listed in any pharmacopoeia for prophylactic or therapeutic treatment of a medical condition or a potential medical condition in a patient.
  • the formulations of the invention may be used to deliver contraceptives, lubricants, anti fungal and anti bacterial substances, and other known pharmacologically active agents for localised use, but may also be used for delivery of immunogenic substances such as vaccines or for other known medical substances for local or systemic treatment of, for example, wounds, ulcers and psoriasis. Any medical application in which mucosal treatment or mucosal delivery of an active agent is advantageous will be suitably treated by formulations of the invention incorporating pharmacologically active agents.
  • Suitable pharmacologically active agents may include anabolic steroids such as methyltestosterone, ethyloestrenol; NSAID drugs (non-steroidal anti ⁇ inflammatory drugs), such as asprin, ibuprofen, indomethacin, ketoprofen; sedatives and hypnotics such as diazepam, lorazepam, oxazepam; the barbiturates, including pentobarbitone, phenobarbitone, chloral hydrate; thyroid hormones such as thyroxine and liothyronine; vaccines such as cholera, diphtheria, hepatitis A, hepatitis B, H.
  • steroids such as methyltestosterone, ethyloestrenol
  • NSAID drugs non-steroidal anti ⁇ inflammatory drugs
  • sedatives and hypnotics such as diazepam, lorazepam, oxazepam
  • influenzae type B influenza, measles, mumps, polio, rubella, pertussis, tenanus, typhoid, yellow fever; anti ⁇ migraines such as ergotamine, methysergide, propranolol, anti-oestrogens such as tamoxifen and clomiphene; beta-blockers such as alprenolol, propranolol; corticosteroids such as betmethasone, budesonide, cortisone, hydrocortisone, prednisolone, clobetasol; female sex hormones such as oestradiol, medroxyprogesterone; fertility drugs such as clomiphene; immune suppressants such as cyclosporin, methotrexate; inhibitors of bone reabsorption such as etridronate; anti-emetics (nausea and vomiting) such as metroclopramide, promethazine; anti-endometrio
  • a pharmaceutical composition suited to insertion into the body cavity of a patient to be treated, said composition comprising one or more pharmacologically active agents, foaming agents, surfactants, thickeners and optionally, when required, vapour pressure reducers.
  • the foaming agent is a pharmaceutically acceptable propellant and more preferably, the foaming agent is n-butane.
  • the composition is a gel at room temperature, until upon application, it expands into a mousse or foam at a rate so as to not cause discomfort, and to a degree sufficient to adequately coat the mucosal surface of the body cavity.
  • compositions of the invention may be suited to treatment of medical conditions in the vaginal, anal, ear, oral and nasal cavities, wound cavities/fissures, or may be suited to treatment of systemic medical conditions via these cavities. They may also be suited to the delivery of immunogenic substances which may pass into the patients circulation for the purposes of generating antibodies via the mucosal lining of the site of application. Suitable pharmacologically active agents for delivery in this embodiment of the invention are those previously listed.
  • Thickeners used according to the invention may be selected from the group comprising povidone, cellulose gums such as sodium carmellose, xanthan gum and other pharmaceutically acceptable thickeners, or combinations thereof. These thickeners may also act as stabilisers for the composition and help it slowly develop from a gel to a foam after application to the body cavity of interest, as well as improving the mucoadhesive qualities of the formulation.
  • Surfactants desirably included in the formulations and compositions of the invention so as to assist in formation of the foam, the emulsification of the vapour pressure reducers, and the solubilisation of the active agents may include but are not limited to nonoxinol, polysorbate, glyceryl stearate, glycol stearate, sorbitan esters, polyoxylated stearates, polyoxylated castor oil, macrogol alkyl ethers such as macrogol lauryl ether, and other pharmaceutically acceptable surfactants or combinations of the foregoing.
  • Suitable foaming agents may be selected from but are not limited to hydrocarbons such as n-butane, chlorofluorocarbons, hydrofluorocarbons, dimethyl ether, nitrogen, nitrous oxide and carbon dioxide. These foaming agents must not cause excessively rapid expansion of the foam in the body cavity of a patient since discomfort and/or pain will result.
  • the foaming agents may be combined with oily substances such as for example caprylic/capric triglycerides which act as vapour pressure reducers or solvents.
  • oily substances such as for example caprylic/capric triglycerides which act as vapour pressure reducers or solvents.
  • vapour pressure reducers or solvents may be used alone or in combination.
  • compositions may also include other excipients such as for example pH buffers, solvents, carriers, diluents and preservatives.
  • pH buffers may include citrates, phosphates or acetates, or other pharmaceutically acceptable buffers.
  • Suitable preservatives may include benzyl alcohol or parabens, and other pharmaceutically acceptable preservatives.
  • Suitable carriers and diluents may include purified water.
  • compositions and formulations of the invention are desirably packaged as a metered aerosol, a single-shot vial, or as a two-compartmental system such as a "bag-in-can" type aerosol product.
  • Packaging in a pressurized container is desirable to mitigate against premature expansion of the mousse.
  • compositions according to the invention preferred ranges of the components of the compositions are as follows.
  • Thickeners may be present in an amount of 0.1 - 30% m/m, more preferably 1.0 - 15% m/m.
  • Surfactants may be present in an amount of 1.0 - 60% m/m, more preferably 4.0 - 40% m/m.
  • pH buffers may be present in an amount of 0 - 10% m/m, more preferably 0.1 - 2.0% m/m.
  • Oily substances may be present in an amount of 1.0 - 30% m/m, more preferably 5.0 - 20% m/m.
  • Preservatives may be present in an amount of 0.01 - 5.0% m/m, more preferably 0.2 - 2.0% m/m.
  • the pharmacologically active agent may be present in varying amounts depending on the profile of the drug, the condition to be treated and whether or not localised or systemic treatment is required. In the case of anti-fungal agents, amounts may vary from 0.05 - 20% m/m.
  • the bulk of the compositions according to the invention is made up by a suitable solvent such as water lower alcohols and glycols and combinations thereof which may be present in amounts of 10 - 95% m/m, more preferably 40 - 80% m/m.
  • a method of treatment of a fungal or bacterial infection of the vagina comprising administering to a patient requiring such treatment an effective amount of a pharmaceutical composition according to the invention wherein the pharmacologically active agent is an anti fungal or anti bacterial agent.
  • the pharmacologically active agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole and terconazole.
  • This formulation is simply prepared by blending all ingredients into the water using an overhead stirrer. Sodium CMC is premixed with part of the nonoxinol 9. Mixing is continued for approximately 30 minutes. The pH and viscosity are adjusted to suit application to a body cavity as a gel.
  • compositions including a pharmacologically active agent according to the invention are as follows:
  • compositions and formulations exemplified in accordance with the invention may be rendered suitable for use by the addition of approximately 10% n-butane in one preferred embodiment.
  • This example compares the retention and distribution of the post foaming gel mousse according the invention with the widely used anti-fungal Canesten® Cream.
  • a and B upper right and left quadrants
  • Region E is a sanitary pad collection means external of the vagina of a patient being treated. Healthy, non-pregnant pre-menopausal women gave informed consent. Following an induction health screen, the subjects were studied twice, with the test or control formulation administered in random order 28 days apart. Canesten cream (Bayer Australia) was radio-labelled (by continuous mixing) with 99mm TcDTPA, so that the administered dose was 4MBq in the standard 6g applicator. 99mm TcDTPA was added to 0.5ml of a formulation according to the invention prior to pressurisation and production of a foaming gel, so that 4MBq was incorporated in the test dose. Preparations were weighed and counted before, and after administration to determine accurately the amount administered. A standard was produced, so that gamma-camera, and gamma counter results could be cross-calibrated. All counts were decay corrected.
  • Simultaneous anterior and posterior images were obtained 15 minutes after dosing and at 15 minute intervals for the first hour. Hourly images were then obtained for 7 hours, with a final image at 24 hours. Geometric mean counts were recorded for the whole vagina, and four arbitrary quadrants, and for an extra- vaginal region. Tomography was obtained at 1, 4 and 7 hours. A sanitary pad was changed after each imaging event, and counted to determine the activity lost. The difference between the sum of the activity seen on the gamma camera, and counted on the sanitary pad, and that administered was the activity not accounted for.
  • FIGS. 2 and 3 show the distribution in a typical subject of the Gel Mousse according to the invention and the Canesten Cream within the vagina over 24 hours.
  • Figure 2 indicates virtually all the dose is equally distributed between the two upper quadrants, and slowly and evenly diffuses into the lower quadrants.
  • the Canesten Cream according to figure 3 is unevenly located in upper quadrant A, with minimal amounts in the other upper quadrant. It also diffuses into the lower quadrants, but remains unevenly distributed in the right hand side of the vagina. This is confirmed by the scintigrams, figures 4 and 5.
  • the scintigrams are in pairs, anterior and posterior.
  • the uneven distribution of the cream mentioned above is clearly seen in these images.
  • Some areas of the vaginal epithelium are not in contact with the cream.
  • the Gel Mousse has expanded fairly rapidly to fill the vaginal cavity, and has given extensive coverage of the epithelium and good retention within the vaginal cavity.
  • the formulations and compositions developed in accordance with the invention result in a product which has a delayed expansion upon application so as to minimise discomfort to a patient.
  • the product may be prepared and stored under pressure as a gel but upon delivery assumes the form of a foam or mousse. Good coverage of the epithelium of the cavity being treated is demonstrably achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations conçues en particulier pour introduire un agent pharmacologiquement actif dans une cavité corporelle en vue du traitement systémique ou de la prophylaxie d'un état médical chez le patient en traitement, ou du traitement localisé ou de la prophylaxie de la surface de muqueuse de la cavité du patient dans laquelle la formulation est introduite. Plus précisément, l'invention concerne des compositions pharmaceutiques appropriées pour le traitement ou la prophylaxie d'états médicaux systémiques ou localisés de la muqueuse. L'invention concerne enfin des procédés de traitement d'infections bactériennes ou fongiques de la muqueuse.
PCT/EP2005/008108 2004-07-29 2005-07-26 Mousse en gel post-moussant WO2006010589A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004904260A AU2004904260A0 (en) 2004-07-29 Post foaming gel mousse
AU20004/904260 2004-07-29

Publications (2)

Publication Number Publication Date
WO2006010589A2 true WO2006010589A2 (fr) 2006-02-02
WO2006010589A3 WO2006010589A3 (fr) 2006-08-03

Family

ID=35672370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008108 WO2006010589A2 (fr) 2004-07-29 2005-07-26 Mousse en gel post-moussant

Country Status (1)

Country Link
WO (1) WO2006010589A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2479891A (en) * 2010-04-27 2011-11-02 David Chamberlain Foaming solution to provide acoustic dampening in the ear canal
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
CN109394694A (zh) * 2018-09-30 2019-03-01 北京兴源联合医药科技有限公司 一种无水泡沫剂
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5186857A (en) * 1988-11-14 1993-02-16 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5500211A (en) * 1994-09-22 1996-03-19 The Gillette Company Soap-free self-foaming shave gel composition
US20060140984A1 (en) * 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
MXPA06001381A (es) * 2003-08-04 2006-05-19 Foamix Ltd Vehiculo de espuma que contiene un gelificante copolimerico anfifilico.
KR20060113657A (ko) * 2003-08-25 2006-11-02 포믹스 리미티드 침투성 약제용 거품제

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US12138311B2 (en) 2009-10-02 2024-11-12 Journey Medical Corporation Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
GB2479891A (en) * 2010-04-27 2011-11-02 David Chamberlain Foaming solution to provide acoustic dampening in the ear canal
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
CN109394694A (zh) * 2018-09-30 2019-03-01 北京兴源联合医药科技有限公司 一种无水泡沫剂

Also Published As

Publication number Publication date
WO2006010589A3 (fr) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2006010589A2 (fr) Mousse en gel post-moussant
Bouckaert et al. In‐vitro Bioadhesion of a Buccal, Miconazole Slow‐release Tablet
AU2002246916B2 (en) Bioadhesive cell foam film of sustained-release delivery
Acarturk Mucoadhesive vaginal drug delivery systems
ES2353694T3 (es) Formulaciones mucoadhesivas semisólidas.
JP5184373B2 (ja) 発泡組成物
US20110195114A1 (en) Transdermal delivery systems for active agents
KR102001163B1 (ko) 전기수력학적으로 수득된 섬유를 포함하는 약학적 조성물, 적용 부위에서 향상된 체류 시간을 갖는 조성물
JP6154803B2 (ja) 膣投与のための迅速溶解性錠剤組成物
TW201201866A (en) A fast dissolving pharmaceutical composition
EP0643963A2 (fr) Dispositif bioérodable pour l'administration d'agents actifs
CN106572970B (zh) 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法
MX2015006399A (es) Composicion para la liberacion inmediata y prolongada.
JP2015522049A (ja) ジクロフェナク製剤
WO2018069888A1 (fr) Compositions pharmaceutiques lyophilisées pour administration vaginale
HUE026213T2 (en) Fast dissolving pharmaceutical preparation
ES2455521T3 (es) Tratamiento de síntomas asociados con la menopausia
Back et al. Comparative pharmacokinetics of levonqrgestrel and ethinyloestradiol following intravenous, oral and vaginal administration
CN113164384A (zh) 黏膜粘附性凝胶组合物
CA2896038C (fr) Compositions de matrice polymere renfermant une concentration elevee d'hyalluonate de sodium bio-fermente et leurs utilisations
US9662340B2 (en) Testosterone gel compositions and related methods
JP5979466B2 (ja) 粘性液組成物
CN101730514A (zh) 用于类固醇阴道释放的新体系的药物组合物
JP3095488B2 (ja) 噴霧用ゲル基剤およびそれを用いた噴霧用点鼻剤
JPS60214732A (ja) 外用貼付剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载